Antipsychotic treatment modulates glutamate transport and NMDA receptor expression (Q38248566)

1 September 2017

1 reference

title

Antipsychotic treatment modulates glutamate transport and NMDA receptor expression (English)

1 reference

1 September 2017

Andrea Schmitt

3

0 references

author name string

Mathias Zink

series ordinal

1

1 reference

PubMed ID

25214389

1 September 2017

Susanne Englisch

series ordinal

2

1 reference

1 September 2017

12 September 2014

1 reference

European Archives of Psychiatry and Clinical Neuroscience

1 September 2017

1 reference

1 September 2017

264 Suppl 1

1 reference

1 September 2017

S67-82

1 reference

https://scigraph.springernature.com/pub.10.1007/s00406-014-0534-4

1 September 2017

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Polypharmacy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

D-serine and schizophrenia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

The neuropsychology of the schizo-obsessive subtype of schizophrenia: a new analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Testing the glutamate hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Neural circuitry models of schizophrenia: is it dopamine, GABA, glutamate, or something else?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Molecular pharmacology of glutamate transporters, EAATs and VGLUTs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Presynaptic NMDA receptors: newly appreciated roles in cortical synaptic function and plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

NMDA receptor subunits: function and pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

NMDA receptors in nervous system diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Glutamate signaling in the pathophysiology and therapy of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

AMPA receptor positive allosteric modulators: a patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Kainate receptors in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Mechanism of differential control of NMDA receptor activity by NR2 subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Differential expression of two glial glutamate transporters in the rat brain: an in situ hybridization study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Glial transporters for glutamate, glycine and GABA I. Glutamate transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Twenty-five years of glutamate in schizophrenia: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Intermediate phenotypes and genetic mechanisms of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Association study of polymorphisms in the glutamate transporter genes SLC1A1, SLC1A3, and SLC1A6 with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Glutamate receptors and transporters in the hippocampus in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Schizophrenia as a developmental disorder of the cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Schizophrenia as a disorder of disconnectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Early life programming and neurodevelopmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

21 January 2018

Rethinking schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Therapeutic targets in major psychiatric disorders revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Clozapine: balancing safety with superior antipsychotic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Receptor mapping: architecture of the human cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Differential effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto-parietal cortex in rats: microdialysis and electrophysiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Deficits of [3H]D-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Autoradiography of [3H]aspartate and glutamate transport in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Quantitative analysis of glutamate transporter mRNA expression in prefrontal and primary visual cortex in normal and schizophrenic brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Selective cortical VGLUT1 increase as a marker for antidepressant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

GLT-1 down-regulation induced by clozapine in rat frontal cortex is associated with synaptophysin up-regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Antipsychotics increase vesicular glutamate transporter 2 (VGLUT2) expression in thalamolimbic pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Clozapine reduces GLT-1 expression and glutamate uptake in astrocyte cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Clozapine-induced reduction of glutamate transport in the frontal cortex is not mediated by GLAST and EAAC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Differential effects of long-term treatment with clozapine or haloperidol on GABA transporter expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Aripiprazole: A New Atypical Antipsychotic Drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Aripiprazole for schizophrenia. Systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Unique pharmacological profile of aripiprazole as the phasic component buster.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Fluoxetine treatment induces EAAT2 expression in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

NMDA receptor and schizophrenia: a brief history

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing isoforms in schizophrenia: postmortem study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Decreased expression of NMDA receptor-associated proteins in frontal cortex of elderly patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

PCP: from pharmacology to modelling schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Prenatal NMDA receptor antagonism impaired proliferation of neuronal progenitor, leading to fewer glutamatergic neurons in the prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

GLT-1 expression and Glu uptake in rat cerebral cortex are increased by phencyclidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Early postnatal depletion of NMDA receptor development affects behaviour and NMDA receptor expression until later adulthood in rats--a possible model for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Neural activation deficits in a mouse genetic model of NMDA receptor hypofunction in tests of social aggression and swim stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Effects of risperidone on glutamate receptor subtypes in developing rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Dopamine partial agonists: a new class of antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Clozapine, GABA(B), and the treatment of resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Neurite outgrowth mediated by the heat shock protein Hsp90α: a novel target for the antipsychotic drug aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Wig-1, a new p53-induced gene encoding a zinc finger protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Neuronal expression of class II major histocompatibility complex (HLA-DR) in 2 cases of Pick disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu₂/₃ receptor agonist, LY379268, is 5-HT₁A dependent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Serotonin 1A receptors in human and monkey prefrontal cortex are mainly expressed in pyramidal neurons and in a GABAergic interneuron subpopulation: implications for schizophrenia and its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

The role of serotonin receptors in the action of atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

D1 but not D2 dopamine receptors or adrenoceptors mediate dopamine-induced potentiation of N-methyl-d-aspartate currents in the rat prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Activation of dopamine D1 receptors blocks phencyclidine-induced neurotoxicity by enhancing N-methyl-D-aspartate receptor-mediated synaptic strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Synthesis and biological activity of some known and putative duloxetine metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

DARPP-32 mediates the actions of multiple drugs of abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Calcium-dependent networks in dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Computational models of schizophrenia and dopamine modulation in the prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-014-0534-4

Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs

21 January 2018

1 reference

12 December 2020

Differential modulation of proliferation in the neocortical ventricular and subventricular zones

1 reference

12 December 2020

Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine

1 reference

12 December 2020

Glutamatergic transmission in schizophrenia: from basic research to clinical practice

1 reference

12 December 2020

Embryonic and early fetal development of the human neocortex

1 reference

12 December 2020

Prenatal developmental disturbances in the limbic allocortex in schizophrenics

1 reference

12 December 2020

Amphetamine regulates gene expression in rat striatum via transcription factor CREB.

1 reference

12 December 2020

Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia

1 reference

12 December 2020

Identification and characterization of a cDNA encoding a neuronal glutamate transporter from Drosophila melanogaster.

1 reference

12 December 2020

Glutamate acting at NMDA receptors stimulates embryonic cortical neuronal migration.

1 reference

12 December 2020

The neurobiology of depression: inroads to treatment and new drug discovery

1 reference

12 December 2020

Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism

1 reference

12 December 2020

Chronic haloperidol treatment impairs glutamate transport in the rat striatum

1 reference

12 December 2020

NICE guidelines address social aspect of schizophrenia

1 reference

12 December 2020

Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex

1 reference

12 December 2020

Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol

1 reference

12 December 2020

Postnatal BDNF expression profiles in prefrontal cortex and hippocampus of a rat schizophrenia model induced by MK-801 administration

1 reference

12 December 2020

Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

An overview of the mechanism of action of clozapine

1 reference

12 December 2020

Expression of parvalbumin and glutamic acid decarboxylase-67 after acute administration of MK-801. Implications for the NMDA hypofunction model of schizophrenia

1 reference

12 December 2020

Gross and histological criteria for developmental disorders in brains of schizophrenics.

1 reference

12 December 2020

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

Facilitative effect of serotonin(1A) receptor agonists on cognition in patients with schizophrenia

1 reference

12 December 2020

What are we looking for in new antipsychotics?

1 reference

12 December 2020

Aripiprazole differentially regulates the expression of Gad67 and γ-aminobutyric acid transporters in rat brain.

1 reference

12 December 2020

Sertindole restores attentional performance and suppresses glutamate release induced by the NMDA receptor antagonist CPP

1 reference

12 December 2020

Clozapine versus typical neuroleptic medication for schizophrenia

1 reference

12 December 2020

Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex.

1 reference

12 December 2020

Glutamatergic animal models of schizophrenia

1 reference

12 December 2020

Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects

1 reference

12 December 2020

Translational and developmental perspective on N-methyl-D-aspartate synaptic deficits in schizophrenia

1 reference

12 December 2020

10.1007/S00406-014-0534-4

Identifiers

DOI

1 reference

PubMed ID

25214389

Dimensions Publication ID

1 September 2017

0 references

1 reference

PubMed ID

25214389